Abstract
We carried out a nested case–control study to measure the rate ratio (RR) for invasive female breast cancer in relation to non-steroidal anti-inflammatory drug (NSAID) use. The source population consisted of the female beneficiaries of the Saskatchewan Prescription Drug Plan from 1981 to 1995 with no history of cancer since 1970. Four controls/case, matched on age and sampling time, were randomly selected. Dispensing rates during successive time periods characterized NSAID exposure. RRs associated with exposure during each period were adjusted for exposure during the others. Confounding by other determinants was studied in analyses adjusted with data obtained by interviewing samples of subjects accrued from mid-1991 to mid-1995. We accrued 5882 cases and 23 517 controls. Increasing NSAID exposure 2–5 years preceding diagnosis was associated with a trend towards a decreasing RR (P -trend = 0.003); for the highest exposure level RR = 0.76, 95% confidence interval 0.63–0.92. This protective effect could not be attributed to confounding by other determinants. In analyses involving only the cases, NSAID exposure 2–5 and 6–10 years preceding diagnosis was associated with significantly reduced risks of presenting with a large tumour (> 5 cm diameter) or distant metastasis, but not regional lymph node metastasis. The use of NSAIDs may retard the growth of breast cancers and prevent distant metastasis. © 2000 Cancer Research Campaign
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Breslow NE and Day NE (1980). Statistical Methods in Cancer Research. Vol. I – The Analysis of Case–control Studies, International Agency for Research on Cancer: Lyon
Cain KC and Breslow NE (1988) Logistic regression analysis and efficient design for two-stage studies. Am J Epidemiol 128: 1198–1206
Collet J-P, Sharpe C, Belzile E, Boivin J-F, Hanley J and Abenhaim L (1999) Colorectal cancer prevention by non-steroidal anti-inflammatory drugs: effects of dosage and timing. Br J Cancer 81: 62–68
Connolly JM and Rose DP (1993) Effects of fatty acids on invasion through reconstituted basement membrane (‘Matrigel’) by a human breast cancer cell line. Cancer Lett 75: 137–142
Connolly JM, Liu XH and Rose DP (1996) Dietary linoleic acid-stimulated human breast cancer cell growth and metastasis in nude mice and their suppression by indomethacin, a cyclooxygenase inhibitor. Nutr Cancer 25: 231–240
Day NE, Byar DP and Green SB (1980) Overadjustment in case–control studies. Am J Epidemiol 112: 696–706
Egan KM, Stampfer MJ, Giovannucci E, Rosner BA and Colditz GA (1996) Prospective study of regular aspirin use and the risk of breast cancer. J Natl Cancer Inst 88: 988–993
Folkman J (1995) The influence of angiogenesis research on management of patients with breast cancer. Breast Cancer Res Treat 36: 109–118
Friedman GD and Ury HK (1980) Initial screening for carcinogenicity of commonly used drugs. J Natl Cancer Inst 65: 723–733
Gammon MD, John EM and Britton JA (1998) Recreational and occupational physical activities and risk of breast cancer. J Natl Cancer Inst 90: 100–117
Gridley G, McLaughlin JK, Ekbom A, Klareskog L, Adami HO, Hacker DG, Hoover R and Fraumeni JF (1993) Incidence of cancer among patients with rheumatoid arthritis. J Natl Cancer Inst 85: 307–311
Han EK, Arber N, Yamamoto H, Lim JT, Delohery T, Pamukcu R, Piazza GA and Xing WQ (1998) Effects of sulindac and its metabolites on growth and apoptosis in human mammary epithelial and breast carcinoma cell lines. Breast Cancer Res Treat 48: 195–203
Harris RE, Namboodiri KK, Stellman SD and Wynder EL (1995) Breast cancer and NSAID use: heterogeneity of effect in a case–control study. Prev Med 24: 119–120
Harris RE, Namboodiri KK and Farrar WB (1996) Non-steroidal anti-inflammatory drugs and breast cancer. Epidemiology 7: 203–205
Hubbard NE, Chapkin RS and Erickson KL (1988) Inhibition of growth and linoleate-enhanced metastasis of a transplantable mouse mammary tumor by indomethacin. Cancer Lett 43: 111–120
Hudson N, Balsitis M, Everitt S and Hawkey CJ (1995) Angiogenesis in gastric ulcers: impaired in patients taking non-steroidal anti-inflammatory drugs. Gut 37: 191–194
Hunter CP, Redmond CK, Chen VW, Austin DF, Greenberg RS, Correa P and Muss HB Forman MR, Wesley MN, Blacklow RS, Kurman RJ, Dignam JJ, Edwards BK and Shapiro S, and other members of the Black/White Cancer Survival Study Group (1993) Breast cancer: factors associated with stage at diagnosis in black and white women. J Natl Cancer Inst 85: 1129–1137
Hwang D, Scollard D, Byrne J and Levine E (1998) Expression of cyclooxygenase-1 and cyclooxygenase-2 in human breast cancer. J Natl Cancer Inst 90: 455–460
Isomäki HA, Hakulinen T and Joutsenlahti U (1978) Excess risk of lymphomas, leukemia and myeloma in patients with rheumatoid arthritis. J Chron Dis 31: 691–696
Khoo NKS, Chan FPH, Saarloos MN and Lala PK (1992) Immunotherapy of mammary adenocarcinoma metastases in C3H/HeN mice with chronic administration of cyclooxygenase inhibitors alone or in combination with IL-2. Clin Exp Metastasis 10: 239–252
Krogh CME (ed) (1995). Compendium of Pharmaceuticals and Specialities, 30th edn, Canadian Pharmaceutical Association: Ottawa
Lala PK, Al-Mutter N and Orucevic A (1997) Effects of chronic indomethacin therapy on the development and progression of spontaneous mammary tumors in C3H/HEJ mice. Int J Cancer 73: 371–380
MacMahon B and Trichopoulos D (1996). Epidemiology. Principles and Methods, 2nd edn. Little, Brown: Boston
Mickey RM and Greenland S (1989) The impact of confounder selection criteria on effect estimation. Am J Epidemiol 129: 125–137
Miettinen OS (1985). Theoretical Epidemiology. Principles of Occurrence Research in Medicine, Delmar: Albany
Parkin DM, Whelan SL, Ferlay J, Raymond L, Young J (eds) (1997). Cancer Incidence in Five Continents, Vol. VII, International Agency for Research on Cancer: Lyon
Rawson NSB, D’Arcy C, Blackburn JL, Bowen RC, Wallace SM, Downey W and Senft D (1992) Epidemiologic research using linked computerized health care datafiles in Saskatchewan, Canada. Technical report series. In Report #2, Psychiatric Pharmacoepidemiology Research Consortium: Saskatoon
Richardson JL, Langholz B, Bernstein L, Burciaga C, Danley K and Ross RK (1992) Stage and delay in breast cancer diagnosis by race, socioeconomic status, age and year. Br J Cancer 65: 922–926
Risch HA and Howe GR (1994) Menopausal hormone usage and breast cancer in Saskatchewan: a record linkage study. Am J Epidemiol 139: 670–683
Robertson FM, Parrett ML, Joarder FS, Ross M, Abou-Issa HM, Alshafie G and Harris RE (1998) Ibuprofen-induced inhibition of cyclooxygenase isoform gene expression and regression of rat mammary carcinomas. Cancer Lett 122: 165–175
Schreinemachers DM and Everson RB (1994) Aspirin use and lung, colon and breast cancer incidence in a prospective study. Epidemiology 5: 138–146
Sharpe CR (1999) Population-based Case–control Study of the Effects of Non-steroidal Anti-inflammatory Drugs on the Risk of Breast Cancer. PhD thesis, McGill University: Montréal
Spiessl B, Sharpe CR, Beahrs OH, Hermanek P, Hutter RVP, Scheibe O, Sobin LH, Wagner G editors (1992). TNM Atlas. Illustrated Guide to the TNM/pTNM Classification of Malignant Tumours, 3rd edn, 2nd revision . Springer-Verlag: Berlin
Taketo MM (1998) Cyclooxygenase-2 inhibitors in tumorigenesis (Part I). J Natl Cancer Inst 90: 1529–1536
Thompson HJ, Briggs S, Paranka NS, Piazza GA, Brendel K, Gross PH, Sperl GJ and Pamukcu R (1995) Inhibition of mammary carcinogenesis in rats by sulfone metabolite of sulindac. J Natl Cancer Inst 87: 1259–1260
Thun MJ, Namboodiri MM, Calle EE, Flanders WD and Heath CW (1993) Aspirin use and risk of fatal cancer. Cancer Res 53: 1322–1327
Thune I, Brenn T, Lund E and Gaard M (1997) Physical activity and the risk of breast cancer. N Engl J Med 336: 1269–1275
Vainio H and Morgan G (1998) Cyclooxygenase 2 and breast cancer prevention. Br Med J 317: 828
Walter SD and Day NE (1983) Estimation of the duration of a preclinical disease state using screening data. Am J Epidemiol 118: 865–886
Ziche M, Jones J and Gullino PM (1982) Role of prostaglandin E1and copper in angiogenesis. J Natl Cancer Inst 69: 475–482
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Sharpe, C., Collet, JP., McNutt, M. et al. Nested case–control study of the effects of non-steroidal anti-inflammatory drugs on breast cancer risk and stage. Br J Cancer 83, 112–120 (2000). https://doi.org/10.1054/bjoc.2000.1119
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1054/bjoc.2000.1119
Keywords
This article is cited by
-
Personalized cancer vaccine strategy elicits polyfunctional T cells and demonstrates clinical benefits in ovarian cancer
npj Vaccines (2021)
-
Use of nonsteroidal anti-inflammatory drugs and breast cancer risk in a prospective cohort of postmenopausal women
Breast Cancer Research (2020)
-
Aspirin mediates histone methylation that inhibits inflammation-related stemness gene expression to diminish cancer stemness via COX-independent manner
Stem Cell Research & Therapy (2020)
-
Roles of prostaglandins in tumor-associated lymphangiogenesis with special reference to breast cancer
Cancer and Metastasis Reviews (2018)
-
New use of low-dose aspirin and risk of colorectal cancer by stage at diagnosis: a nested case–control study in UK general practice
BMC Cancer (2017)